Boston & New England CRE News In Your Inbox.
Sign up for Connect emails to stay informed with CRE stories that are 150 words or less.
Oncorus Taps DPS Group for Clinical Manufacturing Facility
DPS Group has been selected by viral immunotherapies company Oncorus, Inc. to design a 88,000-square-foot viral immunotherapy clinical manufacturing facility on the Innovation Park campus at 4 Corporate Dr. In Andover, MA. DPS is providing architectural, process and MEPFP engineering services in a phased approach.
Oncorus anticipates the first phase of the facility’s buildout will be completed in 2021, including process development and quality control. CQV completion and GMP multi-product manufacturing capabilities and full operation are slated for the first half of 2023.
“We selected DPS due to its robust history performing specialized design services in the life sciences industry,” said Brett Belongia, PhD, VP of CMC operations at Oncorus. “This new GMP viral immunotherapy clinical manufacturing facility demonstrates our commitment to advance innovative treatment solutions aimed at improving outcomes for cancer patients, and our desire to contribute to the long-term success and impact of the Massachusetts biotech sector.”
- ◦Development